Tafolecimab
- Generic Name
- Tafolecimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2225109-03-3
- Unique Ingredient Identifier
- KV2ZKH0NIM
- Background
Tafolecimab is under investigation in clinical trial NCT04031742 (A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia).
- Indication
在控制饮食的基础上，与他汀类药物、或者与他汀类药物及其他降脂疗法联合用药，用于在接受中等剂量或中等剂量以上他汀类药物治疗，仍无法达到低密度脂蛋白胆固醇（LDL-C）目标的原发性高胆固醇血症（包括杂合子型家族性和非家族性高胆固醇血症）和混合型血脂异常的成人患者。
- Associated Conditions
- -
- Associated Therapies
- -
Effectiveness of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-12
- Target Recruit Count
- 1160
- Registration Number
- NCT06683131
- Locations
- 🇨🇳
The affiliated hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-20
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Jinghui Wang
- Target Recruit Count
- 30
- Registration Number
- NCT06421298
- Locations
- 🇨🇳
Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China
Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population
Not Applicable
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2023-10-24
- Target Recruit Count
- 3684
- Registration Number
- NCT06096909
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath